Mary Szela compensation by year
TriSalus Life Sciences Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $463,630 | $518,077 | $601,398 | $600,920 |
| Bonus | $0 | $0 | $0 | $153,120 |
| Stock awards | $0 | $378,772 | $1,973,051 | $2,570,750 |
| Option awards | $52,841 | $1,433,387 | $1,539,500 | $1,482,762 |
| Non-equity incentive | $123,750 | $340,819 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $1,680 | $21,775 | $22,646 | $15,797 |
| Total | $641,901 | $2,692,830 | $4,136,595 | $4,823,349 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TriSalus Life Sciences, Inc. DEF 14A filed March 31, 2026, accession 0001628280-26-022124, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TriSalus Life Sciences, Inc. filed document, accession 0001628280-26-022124. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 300,000 | $2,094,000 | — |
| RSU | 125,000 | $872,500 | — |
| RSU | 63,674 | $444,445 | — |
| RSU | 40,000 | $279,200 | — |
| RSU | 21,089 | $147,201 | — |
| RSU | 9,193 | $64,167 | — |
| RSU | 101,345 | $0 | — |
| RSU | 17,302 | $0 | — |
| Option | 71,875 | — | $11.51 |
| Option | 250,000 | — | $5.55 |
| Option | 18,536 | — | $2.43 |
| Option | 20,689 | — | $10.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in TriSalus Life Sciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 14 award rows shown.
TriSalus Life Sciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mary Szela · this page | Chief Executive Officer and President | $4,823,349 |
| David Patience | Chief Financial Officer | $3,443,628 |
| Richard Marshak | Chief Commercial Officer | $1,556,000 |
Board service
TriSalus Life Sciences board · FY2025How this board is paid
Company policy: TriSalus Life Sciences pays directors a $50,000 cash retainer. As stated in TriSalus Life Sciences's FY2025 proxy.
The full TriSalus Life Sciences compensation record
free company briefThis page is one person within TriSalus Life Sciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TriSalus Life Sciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TriSalus Life Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TLSI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.